These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26989206)
101. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Puvvada SD; Stiff PJ; Leblanc M; Cook JR; Couban S; Leonard JP; Kahl B; Marcellus D; Shea TC; Winter JN; Li H; Rimsza LM; Friedberg JW; Smith SM Br J Haematol; 2016 Sep; 174(5):686-91. PubMed ID: 27072903 [TBL] [Abstract][Full Text] [Related]
102. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074 [TBL] [Abstract][Full Text] [Related]
103. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Barth MJ; Chu Y; Hanley PJ; Cairo MS Br J Haematol; 2016 May; 173(4):597-616. PubMed ID: 27062282 [TBL] [Abstract][Full Text] [Related]
104. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Nowakowski GS; Chiappella A; Witzig TE; Spina M; Gascoyne RD; Zhang L; Flament J; Repici J; Vitolo U Future Oncol; 2016 Jul; 12(13):1553-63. PubMed ID: 27089170 [TBL] [Abstract][Full Text] [Related]
105. Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. Shankar AG; Kirkwood AA; Depani S; Bianchi E; Hayward J; Ramsay AD; Hall GW Br J Haematol; 2016 May; 173(3):421-31. PubMed ID: 26996288 [TBL] [Abstract][Full Text] [Related]
106. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Stamatoullas A; Brice P; Gueye MS; Mareschal S; Chevallier P; Bouabdallah R; Nguyenquoc S; Francois S; Turlure P; Ceballos P; Monjanel H; Bourhis JH; Guillerm G; Mohty M; Biron P; Cornillon J; Belhadj K; Bonmati C; Dilhuydy MS; Huynh A; Bernard M; Chrétien ML; Peffault de Latour R; Tilly H Bone Marrow Transplant; 2016 Jul; 51(7):928-32. PubMed ID: 27042842 [TBL] [Abstract][Full Text] [Related]
107. Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. Pillai V; Tallarico M; Bishop MR; Lim MS Br J Haematol; 2016 May; 173(4):573-81. PubMed ID: 26992145 [TBL] [Abstract][Full Text] [Related]
109. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452 [TBL] [Abstract][Full Text] [Related]
110. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Burkhardt B; Mueller S; Khanam T; Perkins SL Br J Haematol; 2016 May; 173(4):545-59. PubMed ID: 26991119 [TBL] [Abstract][Full Text] [Related]
111. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy. Goldschmidt N; Kleinstern G; Orevi M; Paltiel O; Ben-Yehuda D; Gural A; Libster D; Lavie D; Gatt ME Cancer Chemother Pharmacol; 2016 May; 77(5):1053-60. PubMed ID: 27056383 [TBL] [Abstract][Full Text] [Related]
112. Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918). Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):15-6. PubMed ID: 27007007 [No Abstract] [Full Text] [Related]
113. Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Lipowska-Bhalla G; Fagnano E; Illidge TM; Cheadle EJ Leuk Lymphoma; 2016; 57(6):1269-80. PubMed ID: 27050042 [TBL] [Abstract][Full Text] [Related]
114. Treatment of relapsed and refractory Hodgkin Lymphoma. von Tresckow B; Moskowitz CH Semin Hematol; 2016 Jul; 53(3):180-5. PubMed ID: 27496309 [TBL] [Abstract][Full Text] [Related]
115. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Jabbour E; Kantarjian H Lancet; 2016 Jun; 387(10036):2360-1. PubMed ID: 27080497 [No Abstract] [Full Text] [Related]
116. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04). Murayama T; Fukuda T; Okumura H; Sunami K; Sawazaki A; Maeda Y; Tsurumi H; Uike N; Hidaka T; Takatsuka Y; Eto T; Tsuda H; Fujisaki T; Miyamoto T; Tsuneyoshi N; Iyama S; Nagafuji K; Harada M Int J Hematol; 2016 Jun; 103(6):676-85. PubMed ID: 27084252 [TBL] [Abstract][Full Text] [Related]
117. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG; Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472 [TBL] [Abstract][Full Text] [Related]
118. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690 [TBL] [Abstract][Full Text] [Related]
119. Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada. Kuruvilla J; Ewara EM; Elia-Pacitti J; Ng R; Eberg M; Kukaswadia A; Sharma A Curr Oncol; 2023 Apr; 30(5):4663-4676. PubMed ID: 37232810 [TBL] [Abstract][Full Text] [Related]
120. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Luo C; Wu G; Huang X; Zhang Y; Ma Y; Huang Y; Huang Z; Li H; Hou Y; Chen J; Li X; Xu S Stem Cell Res Ther; 2022 Mar; 13(1):123. PubMed ID: 35317856 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]